• Earlier this month, BioCryst Pharmaceuticals, Inc. issued full-year 2026 earnings guidance, projecting total revenue between US$635,000,000 and US$660,000,000, following its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
• This new revenue outlook provides a clearer benchmark for how management currently views demand for its rare disease therapies and overall business trajectory.
• Now, we’ll consider how BioCryst’s newly issued 2026 revenue guidance range could reshape the existing investment narrative around ORLADEYO-led growth.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

BioCryst Pharmaceuticals Investment Narrative Recap

To own BioCryst today, you need to believe ORLADEYO can remain a durable rare disease franchise while the pipeline gradually adds new revenue streams. The new 2026 revenue guidance of US$635,000,000 to US$660,000,000 gives a firmer near term bar for ORLADEYO-led growth, but it does not fundamentally change the key catalyst around label and patient population expansion, or the biggest risk from product concentration and intensifying HAE competition.

The most relevant recent update alongside this guidance is BioCryst’s raised 2025 revenue outlook, which lifted expected total 2025 revenue to US$560,000,000 to US$575,000,000. Taken together, the 2025 and 2026 ranges frame how management currently sees ORLADEYO’s revenue run rate into the next few years, which matters for assessing how exposed the company remains to a single therapy as rivals like garadacimab and Ekterly gain traction.

Yet, behind these higher revenue targets, there is a concentration risk that investors should be aware of...

BioCryst Pharmaceuticals' narrative projects $777.6 million revenue and $212.3 million earnings by 2028. This requires 11.7% yearly revenue growth and a $248.0 million earnings increase from -$35.7 million.

Uncover how BioCryst Pharmaceuticals' forecasts yield a $20.60 fair value, a 209% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span a wide range, from US$3.53 to US$83.30, showing how far apart individual views can be. When you set that against BioCryst’s reliance on ORLADEYO for most of its revenue, it underlines why many investors look at several perspectives before forming an opinion on the company’s longer term performance.

Explore 5 other fair value estimates on BioCryst Pharmaceuticals - why the stock might be worth 47% less than the current price!

Build Your Own BioCryst Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioCryst Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.